Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07453446) titled 'Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma' on March 1.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Condition:
Relapsed or Refractory Lymphoma
Intervention:
Drug: CD30 CAR-T Cells
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: March 4, 2025
Target Sample Size: 18
Countries of Recruitment:
China
To know more, visit https://clinicalt...